EAG Laboratories Announces Latest Advancement in Transmission Electron Microscopy
9.12.2020 16:00:00 EET | Business Wire | Press release
EAG Laboratories is pleased to announce the completed installation of a ThermoFisher Scientific Themis Z Transmission Electron Microscope (TEM) at our Silicon Valley facility. This next generation, ultra-high-resolution TEM is the first available in an independent laboratory in North America and is the second Themis Z owned by EAG Laboratories.
The Themis Z is a monochromated, probe-corrected TEM operated in an electron energy range of 30-300 kilovolts. Outside of its pure imaging capabilities, the microscope provides unprecedented access to physical and chemical properties for advanced materials research. With this technology, EAG scientists can provide our clients with:
- Sub-atomic spatial resolution
- State-of-the-art chemical analysis
- Revolutionary mapping capability for a wide variety of physical material properties
- Improved atomic resolution for compound semiconductors, atomic layer etching and advanced node devices
This leading edge TEM gives EAG Laboratories’ clients the highest resolution and deeper insights into the materials structure of their devices, which will increase their ability to improve device performance and reduce time to market. The Themis Z complements the company’s existing global microscopy services and strengthens its position as the world leader in advanced microscopy services.
EAG Laboratories is delighted to offer its clients data analysis along with the highest resolution images commercially available from a TEM. The company can now serve its clients in North America, Europe and Asia with these powerful advanced imaging capabilities coupled with its global scientific microscopy staff to solve both the routine and the most challenging materials analysis problems.
About EAG Laboratories
EAG Laboratories is the global leader in materials and engineering sciences and supports thousands of clients with 20+ locations throughout Europe, Asia, and the U.S. For more information visit eag.com. EAG Laboratories’ parent company, Eurofins Scientific, is a multi-billion global leader in scientific testing services with a portfolio of over 200,000 validated analytical methods.
About Eurofins – the global leader in bio-analysis
With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005022/en/
Contact information
FOR MORE INFORMATION
Stuart Mitchell, Marketing Director
+1 408 530 3500
marketing@eurofinsEAG.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TEC reduces pressure on support teams with proactive outage communications powered by Adtran and GOCare11.8.2026 15:15:00 EEST | Press release
Adtran and GOCare today announced that Telephone Electronics Corporation (TEC) has improved outage responses and reduced inbound support tickets using GOCare’s OutageIQ solution integrated with Adtran’s outage notification API and Mosaic One. Serving communities across Mississippi, Alabama and Tennessee, TEC delivers fiber broadband services built on a foundation of community investment and reliable service. By combining proactive notifications with real-time network insights, the service provider can now inform customers as issues are detected while equipping support teams with immediate context. This transparency helps build subscriber trust and streamlines operations. “Reliable connectivity is essential for the communities we serve, and clear communication during an outage makes a real difference,” said David Freytag, VP of integration at TEC. “Before this integration, service disruptions could quickly lead to high call volumes, putting pressure on our teams and leaving subscribers
Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 15:07:00 EEST | Press release
Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier to faster adoption, and just 12% say AI planning governance is fully embedded within their operations. The research
One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 15:00:00 EEST | Press release
Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output is one they can verify and every disclosure is one they can defend," said Barbara Larson, Chief Financial Officer at Workiva. "Getting this right is about
Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 15:00:00 EEST | Press release
Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 14:30:00 EEST | Press release
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise. The transaction is subject to customary closing conditions,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom